Key Points
- Strong antitrust enforcement is expected to continue, but without the use of the novel and untested legal theories that defined the Biden administration approach.
- Regulators are likely to continue to focus...more
On January 16, 2025, the Department of Justice (DOJ) Antitrust Division and the Federal Trade Commission (FTC) (together, the Agencies) released the Antitrust Guidelines for Business Activities Affecting Workers (Guidelines),...more
1/30/2025
/ Antitrust Division ,
Antitrust Provisions ,
Antitrust Violations ,
Competition ,
Compliance ,
Department of Justice (DOJ) ,
Employment Contract ,
Employment Policies ,
Federal Trade Commission (FTC) ,
Independent Contractors ,
Non-Compete Agreements ,
Popular ,
Wage and Hour
On August 11, 2020, the U.S. Court of Appeals for the Ninth Circuit decisively reversed the Federal Trade Commission’s (FTC or Commission) controversial district court win challenging Qualcomm’s licensing practices. In...more
8/18/2020
/ Anticompetitive Behavior ,
Antitrust Violations ,
Appeals ,
Cell Phones ,
Corporate Counsel ,
Federal Trade Commission (FTC) ,
FRAND ,
FTC Act ,
Injunctive Relief ,
Intellectual Property Protection ,
IP License ,
Lack of Evidence ,
Monopolization ,
OEM ,
Patent Royalties ,
Qualcomm ,
Remand ,
Reversal ,
Sherman Act ,
Standard Essential Patents
On February 25, 2019, in FTC v. Shire ViroPharma, Inc., the U.S. Court of Appeals for the Third Circuit confirmed that the Federal Trade Commission (FTC) cannot plead its way into federal court via Section 13(b) of the FTC...more
3/2/2019
/ Administrative Proceedings ,
Administrative Remedies ,
Anti-Competitive ,
Antitrust Violations ,
Appeals ,
Disgorgement ,
Dismissals ,
Federal Pleading Requirements ,
Federal Trade Commission (FTC) ,
FTC Act ,
Generic Drugs ,
Illegal Profits ,
Injunctive Relief ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Remedies ,
Restitution ,
Unfair Competition
The U.S. Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, Inc. triggered a flurry of judicial activity in relation to pharmaceutical patent settlements allegedly involving reverse payments from patent...more